Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | MIF | P14174 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3119866 | 0.89 | TAAR1 (0.67) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL11383498 | 0.83 | TAAR1 (0.65) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL27956999 | 0.82 | TAAR1 (0.48) | TAAR1HDAC1HDAC8HTR2CHTR2B | |
| SCHEMBL1046263 | 0.81 | TAAR1 (0.62) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL21913967 | 0.81 | TAAR1 (0.62) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL386982 | 0.81 | TAAR1 (0.62) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL81245 | 0.81 | TAAR1 (0.62) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL2090576 | 0.81 | TAAR1 (0.62) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL1045499 | 0.81 | TAAR1 (0.62) | TAAR1MIFHDAC1HDAC8IDO1 | |
| SCHEMBL4664652 | 0.81 | TAAR1 (0.62) | TAAR1MIFHDAC1HDAC8IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969623-B2 | Method for the preparation of cinacalcet and intermediates and impurities thereof | Amneal Pharmaceuticals, LLC (US) | 2015-03-03 | — | — | US | claimed |
| EP-2406211-A2 | A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF | Megafine Pharma (P) Ltd. (IN) | 2012-01-18 | — | — | EP | claimed |
| WO-2010103531-A2 | A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2010-09-16 | — | — | WO | claimed |
| EP-2406211-B1 | A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF | MEGAFINE PHARMA P LTD (IN) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017033134-A1 | ENZYMATIC PROCESS FOR THE FOR PREPARATION OF (R)-1-(1-NAPHTHYL) ETHYLAMINE, AN INTERMEDIATE OF CINACALCET HYDROCHLORIDE | LUPIN LIMITED (IN) | 2017-03-02 | — | — | WO | disclosed |
| US-9469593-B2 | Process for preparing cinacalcet hydrochloride | SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) | 2016-10-18 | — | — | US | disclosed |
| US-20150152040-A1 | Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof | AMNEAL PHARMACEUTICALS LLC (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150080608-A1 | PROCESS FOR PREPARING CINACALCET HYDROCHLORIDE | SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) | 2015-03-19 | — | — | US | disclosed |
| US-8969623-B2 | Method for the preparation of cinacalcet and intermediates and impurities thereof | Amneal Pharmaceuticals, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140081048-A1 | Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof | MEGAFINE PHARMA (P) LTD. (IN) | 2014-03-20 | — | — | US | disclosed |
| US-8575395-B2 | Method for the preparation of cinacalcet and intermediates and impurities thereof | Amneal Pharmaceuticals, LLC (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2010103531-A2 | A NEW METHOD FOR THE PREPARATION OF CINACALCET AND NEW INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2010-09-16 | — | — | WO | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | disclosed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
| EP-0046590-B1 | PHEN(ALK)OXY-SUBSTITUTED OXIRANE-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND DRUGS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-05-22 | — | — | EP | disclosed |
| US-4337267-A | HYPOKETONEMIC, HYPOGLYCEMIC, ANTIDIABETIC | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-06-29 | — | — | US | disclosed |
| WO-1982000643-A1 | SUBSTITUTED OXIRANECARBONIC ACIDS,PREPARATION AND PHARMACEUTICAL UTILISATION THEREOF | BYK GULDEN LOMBERG CHEM FAB (DE) | 1982-03-04 | — | — | WO | disclosed |
| EP-0046590-A2 | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080608-A1 | PROCESS FOR PREPARING CINACALCET HYDROCHLORIDE | OTC, SI, CMA1 | TAAR1 2402/4885MIF 2444/4885HDAC1 3384/4885 |
| US-20140081048-A1 | Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof | CMA1, SI, ALDH1A1 | TAAR1 1331/4885MIF 2084/4885HDAC1 1038/4885 |
| US-20150152040-A1 | Method For The Preparation Of Cinacalcet And Intermediates And Impurities Thereof | CMA1, SI, ALDH1A1 | TAAR1 1331/4885MIF 2084/4885HDAC1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.